Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AMG0001 in critical limb ischemia
NL-OMON42192Phase 3Withdrawn
- Sponsor
- AnGes, Inc.
- Start
- Nov 2014
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) and arteriosclerosis obliterans comparing AMG0001 with Placebo (2 arms). Primary endpoint: Time to major amputation of the index leg or all-cause death. Planned start Nov 2014; status: withdrawn.
02
Drugs
beperminogene perplasmid
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on NL-OMON42192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42192.